Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C14H19NO2 |
| Molecular Weight | 233.3062 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C(C1COC2=CC=CC=C2O1)N3CCCCC3
InChI
InChIKey=LYKMMUBOEFYJQG-UHFFFAOYSA-N
InChI=1S/C14H19NO2/c1-4-8-15(9-5-1)10-12-11-16-13-6-2-3-7-14(13)17-12/h2-3,6-7,12H,1,4-5,8-11H2
| Molecular Formula | C14H19NO2 |
| Molecular Weight | 233.3062 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Piperoxan is the first antihistamine was discovered. Piperoxan protected guinea pigs against histamine-induced bronchospasm. The piperoxan has been used to provoke anxiety behaviors in the monkey. Piperoxan is an alpha-adrenergic antagonist. Piperoxan has been claimed to preferentially block presynaptic alpha-adrenoreceptors leading to an increase in noradrenaline release and by this way the postsynaptic alpha-adrenoreceptors blockade may be overcome. There was clear evidence that piperoxan enhanced myocardial performance. Piperoxan is a diagnostic aid used in studies of hypertension.
Approval Year
Doses
| Dose | Population | Adverse events |
|---|---|---|
10 mg single, intravenous Recommended Dose: 10 mg Route: intravenous Route: single Dose: 10 mg Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: |
|
15 mg single, intravenous Recommended Dose: 15 mg Route: intravenous Route: single Dose: 15 mg Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: |
Other AEs: Pulse rapid... |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Pulse rapid | 16 patients | 15 mg single, intravenous Recommended Dose: 15 mg Route: intravenous Route: single Dose: 15 mg Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Role of alpha-2 adrenergic receptors in anti-ulcer effect mechanism of estrogen and luteinising hormone on rats. | 2009-04 |
|
| Nasal trigeminal inputs release the A5 inhibition received by the respiratory rhythm generator of the mouse neonate. | 2004-02 |
|
| Development of a segmented model for a continuous electrophoretic moving bed enantiomer separation. | 2003-12-06 |
|
| Continuous fractionation of enantiomer pairs in free solution using an electrophoretic analog of simulated moving bed chromatography. | 2002-04-12 |
|
| Use of dyes to investigate migration of the chiral selector in CFFE and the impact on the chiral separations. | 2001-08-15 |
|
| Antagonists of adenosine and alpha-2-adrenoceptors reverse the anticonvulsant effects of tizanidine in DBA/2 mice. | 1989-03 |
|
| Norepinephrine inhibition of pulsatile LH release: receptor specificity. | 1986-02 |
|
| Pharmacological properties of (N-dicyclopropylmethyl) amino-2-oxazoline (S 3341), an alpha-2 adrenoceptor agonist. | 1985-07-01 |
|
| [Comparative study of piperoxan and 2-(2-imidazolinyl)-1, 4-benzodioxane (170 150) on pre- and postsynaptic receptors in the rat]. | 1982-07-01 |
|
| Pharmacological characteristics of spinal alpha-adrenoreceptors in rats. | 1981-03 |
|
| The role of alpha receptors in the facilitation of the chemoreflex and inhibition of the carotid occlusion reflex by clonidine. | 1980 |
|
| A comparison of the cardiovascular effects of centrally administered clonidine and adrenaline in the anaesthetized rat. | 1979-01 |
|
| Cardiovascular changes in anaesthetised rats after the intra-hypothalamic administration of adrenaline. | 1978 |
|
| Differentiation of drugs acting centrally upon the cardiovascular system by means of sympathetic and vagal responses. | 1978 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:57:34 GMT 2025
by
admin
on
Mon Mar 31 17:57:34 GMT 2025
|
| Record UNII |
9ZCS27634Y
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29713
Created by
admin on Mon Mar 31 17:57:34 GMT 2025 , Edited by admin on Mon Mar 31 17:57:34 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
149
Created by
admin on Mon Mar 31 17:57:34 GMT 2025 , Edited by admin on Mon Mar 31 17:57:34 GMT 2025
|
PRIMARY | |||
|
9ZCS27634Y
Created by
admin on Mon Mar 31 17:57:34 GMT 2025 , Edited by admin on Mon Mar 31 17:57:34 GMT 2025
|
PRIMARY | |||
|
CHEMBL31836
Created by
admin on Mon Mar 31 17:57:34 GMT 2025 , Edited by admin on Mon Mar 31 17:57:34 GMT 2025
|
PRIMARY | |||
|
100000082193
Created by
admin on Mon Mar 31 17:57:34 GMT 2025 , Edited by admin on Mon Mar 31 17:57:34 GMT 2025
|
PRIMARY | |||
|
m8861
Created by
admin on Mon Mar 31 17:57:34 GMT 2025 , Edited by admin on Mon Mar 31 17:57:34 GMT 2025
|
PRIMARY | Merck Index | ||
|
59-39-2
Created by
admin on Mon Mar 31 17:57:34 GMT 2025 , Edited by admin on Mon Mar 31 17:57:34 GMT 2025
|
PRIMARY | |||
|
SUB09872MIG
Created by
admin on Mon Mar 31 17:57:34 GMT 2025 , Edited by admin on Mon Mar 31 17:57:34 GMT 2025
|
PRIMARY | |||
|
6040
Created by
admin on Mon Mar 31 17:57:34 GMT 2025 , Edited by admin on Mon Mar 31 17:57:34 GMT 2025
|
PRIMARY | |||
|
165963-28-0
Created by
admin on Mon Mar 31 17:57:34 GMT 2025 , Edited by admin on Mon Mar 31 17:57:34 GMT 2025
|
SUPERSEDED | |||
|
C66399
Created by
admin on Mon Mar 31 17:57:34 GMT 2025 , Edited by admin on Mon Mar 31 17:57:34 GMT 2025
|
PRIMARY | |||
|
DTXSID1046269
Created by
admin on Mon Mar 31 17:57:34 GMT 2025 , Edited by admin on Mon Mar 31 17:57:34 GMT 2025
|
PRIMARY | |||
|
Piperoxan
Created by
admin on Mon Mar 31 17:57:34 GMT 2025 , Edited by admin on Mon Mar 31 17:57:34 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |